Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03568656 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate CCS1477 in Advanced Tumours

A Phase 1 study, sponsored by CellCentric.

Completed
Registry status
Phase 1
Development phase
220
Enrollment target

NCT03568656: Completed Phase 1 study, sponsored by CellCentric.

NCT03568656 is a Phase 1 study that has completed, run by CellCentric. The registered enrollment target is 220 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (267% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03568656, a Phase 1 study, has completed, sponsored by CellCentric.

COMPLETED
Registry status
Phase 1
Development phase
220 participants
Enrollment target

Study Summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

Primary Outcome

Treatment-related adverse events and serious adverse events

Interventions

  • DRUG Darolutamide
  • DRUG Olaparib
  • DRUG Enzalutamide
  • DRUG CCS1477
  • DRUG Abiraterone acetate

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2018-07-23
Est. Completion 2025-07-06
Phase Phase 1
CellCentric

3 total trials

What the finished NCT03568656 record still lists

NCT03568656 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (267% higher).

The record links to 0 conditions, and to 5 interventions - of which Darolutamide is the first listed.

NCT03568656 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03568656 about?

NCT03568656 is a clinical study titled "Study to Evaluate CCS1477 in Advanced Tumours". A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

What is the current status of trial NCT03568656?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2018-07-23. Estimated completion is 2025-07-06.

What interventions are being tested in trial NCT03568656?

The interventions under investigation include: Darolutamide (DRUG), Olaparib (DRUG), Enzalutamide (DRUG), CCS1477 (DRUG), Abiraterone acetate (DRUG).

Who is sponsoring clinical trial NCT03568656?

This trial is sponsored by CellCentric, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03568656's enrollment target sits among peer trials

220 230th of 2000 higher than 1,763 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03568656, the US trial registry maintained by the National Library of Medicine. NCT03568656 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.